• Ongoing organic growth driven by new pharmacy wholesale customers and double-digit growth in Southeast Asia
• Disciplined cost management, delivering 20bps cost-out
• All FY25 growth objectives met and EBITDA delivered within guidance

EBOS Group Ltd reported a solid FY25 performance, with ongoing organic growth driven by ~$385m revenue from new pharmacy wholesale customers and double-digit growth in Southeast Asia within Medical Technology, resulting in total underlying Group EBITDA growth of 7.5% (excluding the Chemist Warehouse Australia contract). The company maintained disciplined cost management, delivering 20bps cost-out, and continued strategic execution, meeting all FY25 growth objectives and delivering EBITDA within guidance. EBOS is completing the distribution centre renewal program in FY26, which will have delivered 8 new sites over 4 years, and its bolt-on acquisition program continues in FY26 with the purchase of Next Generation Pet Foods, expanding into high growth premium air-dried treats and enhancing manufacturing capability. EBOS is a leading pharmaceutical wholesaler in Australia and New Zealand, the leading health-services focussed community pharmacy network in Australia, Australia and New Zealand's leading hospital medicines wholesaler and one of ANZ and Southeast Asia's leading medical technology distributors, as well as ANZ's largest dry dog food brand and leading vet wholesaler.

EBOS expects to deliver FY26 Underlying EBITDA growth of 7.5% (excluding the Chemist Warehouse Australia contract).

EBOS remains focused on capital investment and allocation, with the completion of the distribution centre renewal program in FY26 and continued bolt-on acquisitions to strengthen the core and diversify and grow earnings.